The U.S. Food and Drug Administration has granted authorization for the Virtuoso Endoscopy System, a new surgical technology designed to remove bladder tumors.
Developed by Nashville-based Virtuoso Surgical, the device utilizes two needle-sized robotic arms to perform procedures through the urethra.
This approach allows surgeons to remove lesions in one piece, a technique known as en bloc resection, without the need for external skin incisions.
The system operates using a rigid endoscope and a flexible metal alloy, providing surgeons with two-handed control within the confined space of the bladder.
The manufacturer emphasizes that the robot remains entirely under the control of the surgeon and does not operate autonomously.
By keeping the tumor intact, the technology aims to provide pathologists with better tissue samples to determine if cancer has reached the bladder muscle.
Dr. Duke Herrell, a urologic surgeon and CEO of the company, explained the clinical significance of this method in an “official FDA announcement.”
“Removing a tumor intact can provide a better tissue specimen, which supports clearer diagnosis and staging,” Herrell stated, according to the “company’s FDA announcement.”
Early clinical findings from a company-sponsored study in Hong Kong showed that 94% of removed lesions contained the necessary detrusor muscle for evaluation.
However, the study involved a small patient group and did not directly compare the robot to traditional instruments in a randomized trial.
The FDA granted the authorization on Oct. 30, 2026, following a breakthrough device designation issued the previous year.
While the system is approved for adult patients, it does not guarantee improved survival rates or the prevention of cancer recurrence.
Virtuoso Surgical plans to initiate a limited U.S. launch in 2027, focusing initially on prominent urology centers.
Patients are encouraged to discuss the potential benefits of this en bloc resection method with their urologists to understand how tissue samples are collected during their specific procedures.
Future research will be required to determine if the system improves long-term health outcomes for patients diagnosed with bladder cancer.